Loading...
XNAS
DNTH
Market cap4.75bUSD
Oct 08, Last price  
82.43USD
1D
-2.89%
1Q
-15.54%
IPO
649.36%
Name

Magenta Therapeutics Inc

Chart & performance

D1W1MN
XNAS:DNTH chart
P/E
—
P/S
2,264.57
EPS
—
Div yield, %
—
Shrs. gr., 5y
68.96%
Rev. gr., 5y
%
Revenues
2m
-67.35%
000001,476,0006,417,0002,826,0006,235,0002,036,000
Net income
-162m
L+91.05%
-9,431,000-35,491,000-57,515,000-76,769,000-74,936,000-13,109,000-28,476,000-43,555,000-84,969,000-162,337,000
CFO
-129m
L+65.08%
-6,529,000-22,263,000-41,886,000-57,103,000-64,022,999-59,531,000-29,070,000-36,861,000-78,180,000-129,060,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Key people

Jason Ryan
Chief Financial Officer, Chief Operating Officer · since 2019
Li Malmberg
Senior Vice President - Head of Manufacturing · since 2020
Jan Pinkas
Chief Scientific Officer · since 2019
Zoran Zdraveski
Secretary and Chief Legal Officer · since 2017
Jeffrey Albers
Independent Director · since 2017
Alexis Borisy
Independent Director · since 2015
Blake Byers
Independent Director · since 2017
Thomas O. Daniel
Independent Director · since 2016
Anne McGeorge
Independent Director · since 2019
Amy L. Ronneberg
Independent Director · since 2018
Jason Gardner
President, Chief Executive Officer, Co-Founder, Director
URL
https://dianthustx.com/
IPO date
Jun 21, 2018
Employees
67
Domiciled in
US
Incorporated in
US
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
50 Hampshire Street
Cambridge, MA 02139
US
Previous name
MAGENTA THERAPEUTICS, INC.

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT